Switching to an Intravitreal Dexamethasone Implant after Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema: A Review.
- Published in:
- Life (2075-1729), 2024, v. 14, n. 6, p. 725, doi. 10.3390/life14060725
- By:
- Publication type:
- Article
Works matching DE "ABBVIE Inc."
Results: 42
1
2
Small nanobody drugs win big backing from pharma.
- Published in:
- Nature Medicine, 2013, v. 19, n. 11, p. 1355, doi. 10.1038/nm1113-1355
- By:
- Publication type:
- Article
3
NUEVOS DESARROLLOS EN EL SECTOR FARMACÉUTICO. LAS RESOLUCIONES DE ARCHIVO DE LA CNMC EN "INHALADORES ASTRAZENECA" Y "ABBVIE".
- Published in:
- Actualidad Jurídica (1578-956X), 2021, n. 56, p. 166
- By:
- Publication type:
- Article
4
Content marketing at AbbVie.
- Published in:
- Journal of Brand Strategy, 2018, v. 6, n. 4, p. 318, doi. 10.69554/jzcb8474
- By:
- Publication type:
- Article
5
Elagolix for endometriosis: all that glitters is not gold.
- Published in:
- 2019
- By:
- Publication type:
- journal article
6
Investigation of possible aqueous phase formation during vaporization of sevoflurane.
- Published in:
- Journal of Anaesthesiology Clinical Pharmacology, 2019, v. 35, n. 1, p. 76, doi. 10.4103/joacp.JOACP_53_18
- By:
- Publication type:
- Article
7
15 March News.
- Published in:
- Clinical Infectious Diseases, 2014, v. 58, n. 6, p. i, doi. 10.1093/cid/ciu047
- Publication type:
- Article
8
Paritaprevir/ritonavir/ombitasvir plus dasabuvir/Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin.
- Published in:
- Australian Prescriber, 2016, v. 39, n. 4, p. 141, doi. 10.18773/austprescr.2016.045
- Publication type:
- Article
9
NIH denies march-in rights on Norvir patent.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 12, p. 898, doi. 10.1038/nrd4198
- By:
- Publication type:
- Article
10
Deal watch: AbbVie invests in pioneering celiac disease therapy.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 7, p. 497, doi. 10.1038/nrd4063
- By:
- Publication type:
- Article
11
AbbVie's Venclexta Access Solutions.
- Published in:
- 2018
- Publication type:
- Product Review
12
Venclexta Approved in Combination for Older Adults with Acute Myeloid Leukemia.
- Published in:
- Oncology Practice Management, 2018, v. 8, n. 12, p. 23
- Publication type:
- Article
13
Has the COVID-19 Pandemic Led to a Switch in the Volatility of Biopharmaceutical Companies?
- Published in:
- Mathematics (2227-7390), 2023, v. 11, n. 14, p. 3116, doi. 10.3390/math11143116
- By:
- Publication type:
- Article
14
Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients.
- Published in:
- Ophthalmology & Therapy, 2022, v. 11, n. 3, p. 1147, doi. 10.1007/s40123-022-00493-z
- By:
- Publication type:
- Article
15
SOUTHEASTERN PENNSYLVANIA TRANSPORTATION AUTHORITY v. ABBVIE INC./JAMES RIZZOLO v. ABBVIE INC.
- Published in:
- 2015
- Publication type:
- Opinion
16
Good 2016 for US pharma.
- Published in:
- Chemistry & Industry, 2017, v. 81, n. 2, p. 10, doi. 10.1002/cind.812_3x
- Publication type:
- Article
17
Taxing issue.
- Published in:
- 2014
- Publication type:
- Opinion
18
New Levodopa Infusion Systems for Advanced Parkinson's Disease.
- Published in:
- touchREVIEWS in Neurology, 2024, v. 20, n. 1, p. 23, doi. 10.17925/usn.2024.20.1.5
- By:
- Publication type:
- Article
19
AbbVie pays $21 billion for Pharmacyclics' BTK inhibitor.
- Published in:
- Nature Reviews Drug Discovery, 2015, v. 14, n. 4, p. 227, doi. 10.1038/nrd4605
- By:
- Publication type:
- Article
20
Patent watch: Stelara safe after IL-12 antibody dispute.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 9, p. 647, doi. 10.1038/nrd4423
- By:
- Publication type:
- Article
21
Sponsors.
- Published in:
- Andrology, 2016, v. 4, p. 95, doi. 10.1111/andr.12272
- Publication type:
- Article
22
Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity.
- Published in:
- British Journal of Clinical Pharmacology, 2020, v. 86, n. 11, p. 2274, doi. 10.1111/bcp.14330
- By:
- Publication type:
- Article
23
Top Foreign Corporate Citizens.
- Published in:
- Corporate Knights, 2016, v. 15, n. 3, p. 36
- Publication type:
- Article
24
SID 2015 Contributors.
- Published in:
- Journal of Investigative Dermatology, 2015, v. 135, n. 12, p. 3212, doi. 10.1038/jid.2015.397
- Publication type:
- Article
25
Should patients be advised not to drive for 4 days after isoflurane anaesthesia?
- Published in:
- 2017
- By:
- Publication type:
- Editorial
26
Company Profiles.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2018, v. 14, p. 55, doi. 10.1111/ajco.12991
- Publication type:
- Article
27
Company Profiles.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2017, v. 13, p. 65, doi. 10.1111/ajco.12720
- Publication type:
- Article
28
Company Profiles.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2014, v. 10, p. 47, doi. 10.1111/ajco.12224
- Publication type:
- Article
29
ASQ NEWS.
- Published in:
- Quality Progress, 2013, v. 46, n. 10, p. 17
- Publication type:
- Article
30
Seven days: 6-12 March 2015.
- Published in:
- Nature, 2015, v. 519, n. 7542, p. 134, doi. 10.1038/519134a
- Publication type:
- Article
31
Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study.
- Published in:
- British Journal of Dermatology, 2019, v. 181, n. 6, p. 1177, doi. 10.1111/bjd.18029
- By:
- Publication type:
- Article
32
AbbVie buys last available priority voucher for $350 million.
- Published in:
- Nature Biotechnology, 2015, v. 33, n. 11, p. 1120, doi. 10.1038/nbt1115-1120
- By:
- Publication type:
- Article
33
Industry chases pan-genotypic and shorter HCV treatments.
- Published in:
- Nature Biotechnology, 2015, v. 33, n. 6, p. 575, doi. 10.1038/nbt0615-575
- By:
- Publication type:
- Article
34
Big-cap buying bonanza trickles down to small biotech.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 11, p. 1077, doi. 10.1038/nbt1114-1077
- By:
- Publication type:
- Article
35
First PI3k inhibitor launches into crowded hematology markets.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 10, p. 963, doi. 10.1038/nbt1014-963
- By:
- Publication type:
- Article
36
AbbVie drops transparency fight.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 6, p. 507, doi. 10.1038/nbt0614-507b
- By:
- Publication type:
- Article
37
Ethical drug updates: The latest drug announcements and PBS listings.
- Published in:
- 2018
- Publication type:
- Product Review
38
Ethical drug updates: The latest drug announcements and PBS listings.
- Published in:
- 2017
- Publication type:
- Product Review
39
Hep C circuitbreaker.
- Published in:
- Australian Journal of Pharmacy, 2016, p. 6
- Publication type:
- Article
40
Inside AbbVie.
- Published in:
- Australian Journal of Pharmacy, 2013, v. 94, n. 1115, p. 17
- Publication type:
- Article
41
AbbVie launches Down Under.
- Published in:
- Australian Journal of Pharmacy, 2013, v. 94, n. 1114, p. 61
- Publication type:
- Article
42
Sustaining an efficient and effective CHO cell line development platform by incorporation of 24‐deep well plate screening and multivariate analysis.
- Published in:
- Biotechnology Progress, 2018, v. 34, n. 1, p. 175, doi. 10.1002/btpr.2584
- By:
- Publication type:
- Article